Inhibiting the KEAP1/NRF2 interaction, and hence proteasomal degradation, promotes the intracellular concentration of NRF2.[84] This increase plays a key role in anti‐oxidant processes to prevent neurodegenerative diseases such as Huntington's and Parkinson's.[85] Previous research[86] identified an oligopeptide as the minimal binding sequence to the Kelch domain of KEAP1. The gene discussed is KEAP1; the disease is Parkinson disease.